Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes

Details for Australian Patent Application No. 2002252636 (hide)

Owner Biosite Incorporated

Inventors Valkirs, Gunars E; Dahlen, Jeffrey R; Buechler, Kenneth F

Agent Spruson & Ferguson

Pub. Number AU-B-2002252636

PCT Pub. Number WO2002/083913

Priority 09/835,298 13.04.01 US

Filing date 11 April 2002

Wipo publication date 28 October 2002

Acceptance publication date 8 March 2007

International Classifications

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

C07K 14/575 (2006.01) Peptides having more than 20 amino acids

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

17 April 2003 Application Open to Public Inspection

  Published as AU-B-2002252636

28 August 2003 Change of Name(s) of Applicant(s), Section 104

  Biosite Diagnostics, Inc. The name of the applicant has been changed to Biosite Incorporated

8 March 2007 Application Accepted

  Published as AU-B-2002252636

5 July 2007 Standard Patent Sealed

3 March 2011 Alteration of Name

  The name of the patentee has been altered to Alere San Diego, Inc. 2004

26 April 2012 Assignment Registered

  Alere San Diego, Inc. ( General Electric Capital Corporation )

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002252637-HIGH PRESSURE PROCESSING CHAMBER FOR SEMICONDUCTOR SUBSTRATE INCLUDING FLOW ENHANCING FEATURES

2002252635-JACK-UP MODU AND JACKING METHOD AND APPARATUS